FindTrial
Sign In

Clinical Application and Demonstration of the First-in-Human Cerebrovascular Targeted Drug-Eluting Stent

Clinical Application and Demonstration of the First-in-Human Cerebrovascular Targeted Drug-Eluting Stent

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2600126764
Enrollment
Unknown
Registered
2026-06-15
Start date
2026-06-15
Completion date
Unknown
Last updated
2026-06-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Vertebral Artery Stenosis

Interventions

Stent implantation group:None

Sponsors

Renji Hospital affiliated to Shanghai Jiaotong University School of Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: All patients with symptomatic extracranial vertebral artery stenosis who received the Bridge stent in a real-world setting were included in this analysis.

Exclusion criteria

Exclusion criteria: Individuals who refused to participate in the study, refused to follow up, or refused to provide relevant information.

Design outcomes

Secondary

MeasureTime frame
All-cause mortality during follow-up;MRS scale follow-up;Incidence of target vessel-related stroke or death;Incidence of in-stent restenosis (stenosis degree > 50%;Incidence of stroke or neurological death;Immediate stent implantation success rate;—

Countries

China

Contacts

Public ContactWan Jieqing

Renji Hospital affiliated to Shanghai Jiaotong University School of Medicine

jieqingwan@126.com+86 18901661088

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Jun 29, 2026